Expert reporting and analysis connecting R&D, commercial strategy and dealmaking — so you understand not just what’s happening, but what it means for your business.
Every story connects developments to strategic impact — explaining why it matters and who it affects across your market and pipeline.
Reporters on the ground in the US, Europe, China, Japan, India and Korea with direct access to executives, KOLs and analysts.
Built to brief boards, inform quarterly reviews and prepare teams for earnings Q&As — not just to inform.
Stay ahead of the developments shaping the global biopharma industry with expert analysis that frames each story in strategic context — not just the facts, but the implications.
Scrip goes beyond reporting to help biopharma leaders interpret what’s happening and plan their next move — with commercial analysis tailored for CI, BD&L and portfolio teams.
Scrip’s reporting is shaped by years of biopharma experience and collaboration with Norstella’s data and analyst teams — bringing exclusive access and proprietary insight unavailable anywhere else.
Track drug discovery, development and clinical progress with the strategic implications explained — not just the data.
Deeper insight into deals and fundraising including strategic rationale, competitive dynamics and valuation implications.
Build competitive landscape intelligence with profiles of high-growth companies across therapeutic areas.
Dedicated coverage of China, Japan, India and Korea with reporters on the ground and exclusive executive access.
Original data-driven reports powered by Norstella forecasting and analyst insights to surface commercial signals early.
Market access, reimbursement and regulatory developments framed for commercial and BD&L decision-makers.
Scrip’s depth and credibility means it’s regularly used to brief leadership teams, inform quarterly business reviews, and prepare spokespeople for earnings season questions. Cited by top-tier consultants and investment firms in due diligence and investment memos.
CI, BD&L and portfolio teams use Scrip’s commercial analysis to surface the strategic impact of developments on assets, markets and competitors — reducing reliance on expensive external research.
Scrip covers the full arc of biopharma dealmaking — from early biotech financing through major licensing and M&A — with the strategic rationale and competitive implications explained every time.
Content is tagged and organized by disease area, region and strategic focus, so teams receive focused delivery on the markets and pipelines most relevant to them — not a firehose of undifferentiated news.
Biopharma executives use Scrip to stay ahead of industry moves and prepare for board discussions and investor conversations.
Teams evaluating deals and managing pipelines rely on Scrip's commercial analysis and deal intelligence for due diligence and valuation context.
CI teams use Scrip to monitor competitor moves, pipeline developments and market signals across therapy areas and geographies.
IR and comms professionals use Scrip to track how the industry covers their peers and to anticipate the questions they'll face.
Analysts, bankers and consultants cite Scrip in due diligence, investment memos and client briefings as a trusted primary source.
R&D executives track competitor pipelines, trial outcomes and emerging science to benchmark their own programs and identify opportunities.
Citeline’s award-winning publications provide in-depth coverage of the pharmaceutical industry, thanks to 40+ in-house journalists who tackle the tough issues with precision, persistence and passion.
Our editorial team spans key biopharma hubs across the US, Europe and Asia, with deep expertise across key therapeutic areas including oncology, cardiometabolic disease, immunology and neurology, as well as in company strategy, financing, dealmaking and more.
Scrip was awarded the National Gold for data-driven insights at the Folio: Eddie & Ozzie Awards, recognizing excellence in pharma journalism. Scrip also won the National Gold Award in Data Journalism in the American Society of Business Publication Editors Awards (AZBEE) in both 2025 and 2026, as well as Editorial Team of the Year in 2025 in the Eddie and Ozzie Awards.
Scrip is Citeline’s premium global publication for biopharma commercial leaders. It delivers expert reporting and analysis on R&D, dealmaking, pipelines and commercial strategy — connecting each development to its strategic implications rather than just reporting the headline.
Scrip serves biopharma executives, BD&L teams, competitive intelligence professionals, investor relations, corporate communications, financial services and consulting firms who need decision-grade intelligence, not general news.
Scrip’s reporting is shaped by in-house analysts, direct executive access and collaboration with Norstella’s data teams. Every story connects developments to strategic impact. It’s regularly cited in board briefings, due diligence memos and investment research.
Yes. API access is available to integrate Scrip directly into internal systems, chat tools and company news feeds so insights surface where decisions happen, rather than requiring teams to visit a separate platform.
Yes. Content is tagged by disease area, region and strategic focus, including a dedicated Focus on Asia section covering China, Japan, India and Korea. This enables personalized delivery tailored to your team’s specific markets and pipelines.
